Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.91
ALXA's Cash to Debt is ranked higher than
59% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. ALXA: 0.91 )
ALXA' s 10-Year Cash to Debt Range
Min: 0.91   Max: No Debt
Current: 0.91

Equity to Asset -0.37
ALXA's Equity to Asset is ranked lower than
59% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. ALXA: -0.37 )
ALXA' s 10-Year Equity to Asset Range
Min: -0.6   Max: 0.84
Current: -0.37

-0.6
0.84
Interest Coverage 1.18
ALXA's Interest Coverage is ranked lower than
56% of the 431 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. ALXA: 1.18 )
ALXA' s 10-Year Interest Coverage Range
Min: 1.18   Max: 9999.99
Current: 1.18

1.18
9999.99
F-Score: 3
Z-Score: -5.86
M-Score: 15.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 3.70
ALXA's Operating margin (%) is ranked higher than
64% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. ALXA: 3.70 )
ALXA' s 10-Year Operating margin (%) Range
Min: -16197.53   Max: 3.7
Current: 3.7

-16197.53
3.7
Net-margin (%) -82.81
ALXA's Net-margin (%) is ranked lower than
52% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. ALXA: -82.81 )
ALXA' s 10-Year Net-margin (%) Range
Min: -12026.75   Max: -3.45
Current: -82.81

-12026.75
-3.45
ROA (%) -84.16
ALXA's ROA (%) is ranked lower than
57% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. ALXA: -84.16 )
ALXA' s 10-Year ROA (%) Range
Min: -224.46   Max: -2.16
Current: -84.16

-224.46
-2.16
ROC (Joel Greenblatt) (%) 11.81
ALXA's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.90 vs. ALXA: 11.81 )
ALXA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -518.48   Max: 11.81
Current: 11.81

-518.48
11.81
Revenue Growth (%) -28.20
ALXA's Revenue Growth (%) is ranked lower than
53% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. ALXA: -28.20 )
ALXA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 85.6
Current: -28.2

0
85.6
EPS Growth (%) 106.60
ALXA's EPS Growth (%) is ranked higher than
98% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. ALXA: 106.60 )
ALXA' s 10-Year EPS Growth (%) Range
Min: -74.2   Max: 106.6
Current: 106.6

-74.2
106.6
» ALXA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ALXA Guru Trades in

Q2 2012

ALXA Guru Trades in Q2 2012

Jim Simons 27,741 sh (+24.43%)
» More
Q3 2012

ALXA Guru Trades in Q3 2012

Jim Simons 158,201 sh (+470.28%)
» More
Q4 2012

ALXA Guru Trades in Q4 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ALXA



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Alexza Pharmaceuticals Inc

Royal Caribbean and Four Others Report $100 Thousand CEO Buys
Over the past week, we have seen five CEOs report insider buys costing them over $100,000. These buys can be significant to note because CEOs are expected to have the most knowledge about their companies and would likely only invest their own money if they expect the share price to rise. Read more...
President and CEO of Alexza Pharmaceuticals Inc. Thomas Braxton King Bought 40,000 Shares
Alexza Pharmaceuticals Inc. was incorporated on Dec. 19, 2000, as FaxMed Inc and later changed its name to Alexza Pharmaceuticals. The company is a pharmaceutical development company focused on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system or CNS conditions. Alexza's primary activities since incorporation have been establishing its offices, recruiting personnel, conducting research and development, conducting preclinical studies and clinical trials, performing business and financial planning, and raising capital. Alexza Pharmaceuticals Inc. has a market cap of $73.1 million; its shares were traded at around $4.62 with and P/S ratio of 22.30. Read more...
Weekly CEO Buys Highlight: NYLD, ALXA, DOC, NTWK, SNV
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/S 1.70
ALXA's P/S is ranked higher than
84% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. ALXA: 1.70 )
ALXA' s 10-Year P/S Range
Min: 1.25   Max: 2725
Current: 1.7

1.25
2725
EV-to-EBIT 35.59
ALXA's EV-to-EBIT is ranked higher than
74% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.97 vs. ALXA: 35.59 )
ALXA' s 10-Year EV-to-EBIT Range
Min: 8.4   Max: 479.3
Current: 35.59

8.4
479.3
Current Ratio 4.56
ALXA's Current Ratio is ranked higher than
86% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. ALXA: 4.56 )
ALXA' s 10-Year Current Ratio Range
Min: 0.63   Max: 10.75
Current: 4.56

0.63
10.75
Quick Ratio 4.23
ALXA's Quick Ratio is ranked higher than
87% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. ALXA: 4.23 )
ALXA' s 10-Year Quick Ratio Range
Min: 0.6   Max: 10.75
Current: 4.23

0.6
10.75

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.20
ALXA's Price/Median PS Value is ranked higher than
99% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. ALXA: 0.20 )
ALXA' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 274.44
Current: 0.2

0.15
274.44
Earnings Yield (Greenblatt) 2.80
ALXA's Earnings Yield (Greenblatt) is ranked higher than
61% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.00 vs. ALXA: 2.80 )
ALXA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 12
Current: 2.8

0.2
12
Forward Rate of Return (Yacktman) -102.17
ALXA's Forward Rate of Return (Yacktman) is ranked lower than
54% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. ALXA: -102.17 )
ALXA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -202.4   Max: -83.9
Current: -102.17

-202.4
-83.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:N3VN.Germany
Alexza Pharmaceuticals, Inc. is incorporated in the state of Delaware on December 19, 2000 as FaxMed, Inc. In June 2001, it changed the name to Alexza Corporation and in December 2001 it became Alexza Molecular Delivery Corporation. In July 2005, it changed the name to Alexza Pharmaceuticals, Inc. It is a pharmaceutical company focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. ADASUVE, or Staccato loxapine, and its product candidates are based on its proprietary technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of the Company's product candidates are subject to extensive regulation by governmental authorities in the United States and other countries. The pharmaceutical and biotechnology industries are intensely competitive. Many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations are actively engaged in research and development of products targeting the same markets as ADASUVE and its other product candidates.
» More Articles for ALXA

Headlines

Articles On GuruFocus.com
Wrong Marketing Lesson by Big Pharma May 03 2014 
Weekly CEO Buys Highlight: RCL, PSXP, ALXA, PAY, HAFC Aug 05 2013 
Royal Caribbean and Four Others Report $100 Thousand CEO Buys Jul 31 2013 
President and CEO of Alexza Pharmaceuticals Inc. Thomas Braxton King Bought 40,000 Shares Jul 29 2013 
Weekly CEO Buys Highlight: NYLD, ALXA, DOC, NTWK, SNV Jul 29 2013 
Alexza Pharmaceuticals Inc. (ALXA) SVP, CFO & Sec August J Moretti sells 10,000 Shares May 07 2010 
cooldecency99 note on ALXA May 01 2010 
Alexza Pharmaceuticals Inc. (ALXA) SVP, CFO & Sec August J Moretti sells 14,000 Shares Dec 21 2009 
Alexza Pharmaceuticals Inc. (ALXA) Pres & CEO Thomas Braxton King sells 45,000 Shares Dec 21 2009 
Weekly CEO Buy Highlight: Winmark Corp, Alexza Pharmaceuticals Inc, Ladenburg Thalmann Financial Ser Oct 11 2009 

More From Other Websites
Alexza to Report 2014 Second Quarter Financial Results on Thursday, August 7, 2014 Jul 17 2014
Alexza to Report 2014 Second Quarter Financial Results on Thursday, August 7, 2014 Jul 17 2014
ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers Jul 08 2014
Alexza Announces the Promotion of Edwin S. Kamemoto, Ph.D. to Senior Vice President, Regulatory... Jun 30 2014
ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 30 2014
Alexza Announces the Promotion of Edwin S. Kamemoto, Ph.D. to Senior Vice President, Regulatory... Jun 30 2014
ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Jun 16 2014
ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 11 2014
Teva launching 3 drugs in 2014 with combined peak sales of $1 bln May 20 2014
Morgan Stanley reports 5.0% passive stake in Alexza Pharmaceuticals May 16 2014
ALEXZA PHARMACEUTICALS INC. Financials May 10 2014
Alexza Pharmaceuticals management to meet with Roth Capital May 09 2014
Alexza Pharmaceuticals' (ALXA) CEO Tom King on Q1 2014 Results - Earnings Call Transcript May 05 2014
Alexza Pharmaceuticals, Inc. Earnings Call scheduled for 5:00 pm ET today May 05 2014
Alexza Pharmaceuticals, Inc. Discusses Q1 2014 Results (Webcast) May 05 2014
ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2014
Alexza Reports 2014 First Quarter Financial Results May 05 2014
Q1 2014 Alexza Pharmaceuticals, Inc. Earnings Release - After Market Close May 05 2014
Alexza Pharmaceuticals Announces the Launch of ADASUVE® (inhalation powder, loxapine) in the Nordic... Apr 30 2014
ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide